Linomide Does Not Prevent Spontaneous Autoimmune Thyroiditis in NOD Mice

References

• Makino S, Kunimolo K, Muraoka Y, Milushima Y., Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1480; 29: 1–13
   Google Scholar
• Bernard N F, Ertug F, Margolese H. High incidence of thyroiditis and anti-thyroid autoantibodies in NOD mice. diabetes 1991; 41: 40–46
   Web of Science ®Google Scholar
• Rasooly L., Burek C L, Rose N. R. Iodine-induced autoimmune thyroiditis in NOD-H-2H4 mice. Clin Immunol Imnumopatliol 1996; 81: 287–292
   PubMedGoogle Scholar
• Karussis D M, Lehmann D., Slavin S, et al. Immunomodula-tion of autoimmunity by Linomide. Isr J Med Sci 1995; 31: 38–41
   PubMedGoogle Scholar
• Kalland T, Aim G, Stålhandske T. Augmentation of mouse natural killer cell activity by LS 2616. a new immunomodu-lator. J. Immunol 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Larsson E L. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Slavin S, Sidi H, Weiss L, Rosenman E, Kalland T, Gross D. Linomide, a new treatment for autoimmune diseases: The potential in Type I diabetes. Diabetes Metab Rev 1993; 9: 311–315
   PubMedGoogle Scholar
• Rapoport M J, Weiss L, Mor A, Bistritzer T, Ramot Y, Slavin S. Prevention of autoimmune diabetes by Linomide in non-obese diabetic (NOD) mice is associated with up-regulation of the TCR-Mediated activation of p21 -ras 1. J Immunol 1996; 157: 4721–4725
   PubMed Web of Science ®Google Scholar
• Gross D J, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994; 37: 1195–1201
   PubMed Web of Science ®Google Scholar
• Slavin S, Weiss L, Wenlang X., Gross D. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (Quin-oline-3-carboxamide). Cell Transplant 1996; 5: 627–630
   PubMed Web of Science ®Google Scholar
• Slavin S, Gross D, Weiss L. Prevention and treatment of type 1 diabetes in NOD mice by Linomide. Transplant Proc 1995; 27: 3240–3240
   PubMed Web of Science ®Google Scholar
• Coutant R, Landais P, Rosilio M, et al. Low dose Linomide in type 1 juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998; 41: 1040–1046
   PubMed Web of Science ®Google Scholar
• Hutchings P, Hedlund G., Dawe K, Howlett S, Cooke A. Effect of the synthetic immunomodulator, Linomide, on experimental models of thyroiditis. Immunology 1999; 96: 340–347
   PubMed Web of Science ®Google Scholar
• Bjöirk J, Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 1989; 27: 319–321
   PubMedGoogle Scholar
• Lehmann D, Karussis D, Fluresco M., et al. Imuuinoinodu-lalion of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol 1997; 74: 102–110
   PubMed Web of Science ®Google Scholar
• Tarkowski A, Gunnarsson K, Nilsson L Å, Lindholm L, Stålhandske T. Successful treatment of autoimmunity in MRL/I mice with LS-2616. a new immunomodulaior. Arthritis Klieum 1986; 29: 1405–1409
   PubMed Web of Science ®Google Scholar
• Karussis D, Lehmann M., Slavin D. S., et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann Neurol 1993; 34: 654–660
   PubMed Web of Science ®Google Scholar
• Karussis D M, Lehmann D., Slavin S, et al. Treatment of chronic-relapsing experimental autoimmune encphalomyeli-lis with the synthetic immunomodulator linomide (quino-line-3-carboxamide). Proc Natl Acad Sci 1993; 90: 6400–6404
   PubMed Web of Science ®Google Scholar
• Tarkowski Gunnarsson A., St K., ålhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZBxNZW) Fl hybrid mice. Immunology 1986; 59: 589–594
   PubMed Web of Science ®Google Scholar
• Meiner M., Karussis D Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide. Neurology 1996; 47: 341–346
   PubMed Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990; 144: 4472–4476
   PubMed Web of Science ®Google Scholar
• Bengtsson M., Sinionsson Carlsson B.K., et al. Stimulation of NK cell. T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. Transplantion 1992; 53: 882–888
   PubMed Web of Science ®Google Scholar
• Tian W-Navikas Z. V., Matusevicius D, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand 1998; 98: 94–101
   PubMed Web of Science ®Google Scholar
• Arad G, Katzellenbogen M., Levy R, Slavin S., Kacmpfer R. Linomide. an immunomodulator thai inhibits Thl cytokine gene expression. Int Immunol 1996; 8: 1603–1607
   PubMed Web of Science ®Google Scholar
• Rasmussen Å, Bech K. K., Feldt-Rasmussen U, et al. Inter-leukin-1 affects the function of cultured human thyroid cells. Allergy 1988; 43: 435–441
   PubMed Web of Science ®Google Scholar
• Rasmussen Å, Kayser K. L., Feldt-Rasmussen Bendtzen U. K. Influence of TNK-alfa, TNF-beta and INF-gamma. separately and combined with lL-lbeta, on the function of cultured human thyroid cells. J Endocrinol 1994; 143: 359–365
   PubMed Web of Science ®Google Scholar
• Christensen U B, Mauricio D, Reiniers J. I., et al. Linomide increases plasma corlicoslcrone in normal rats, but does not prevent the inhibitory action of IL-I on beta cells in vivo or ex vivo. Autoimmunity 1996; 23: 257–268
   PubMed Web of Science ®Google Scholar
• Karussis D M, Lehmann D, Brenner T, et al. Immunomodulation of experimental autoimmune myasthenia gravis with Linomide. J. Neuroimmunol 1994; 55: 187–193
   PubMed Web of Science ®Google Scholar